Yosipovitch, Gil
Nedorost, Susan T.
Silverberg, Jonathan I.
Friedman, Adam J.
Canosa, Juliana M. http://orcid.org/0000-0002-2095-5096
Cha, Amy
Funding for this research was provided by:
Pfizer
Article History
Accepted: 20 December 2022
First Online: 17 February 2023
Declarations
:
: GY has been a consultant and an advisor for Pfizer Inc., Bellus, Eli Lilly and Company, Galderma, Kiniksa, LEO Pharma Novartis, Sanofi-Regeneron, and Trevi Therapeutics and is a principal investigator for Pfizer Inc., Kiniksa, LEO Pharma, Galderma, and Sanofi-Regeneron. JS served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-LaRoche, Menlo Therapeutics, Realm Therapeutics, Regeneron, and Sanofi; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; and as a speaker for Regeneron and Sanofi. JMC and AC are employees and stockholders of Pfizer Inc. AF has been a consultant and advisor for Pfizer Inc., AbbVie, Aveeno, Dermavant, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Graegis, Galderma, Janssen, L'Oréal, Microcures, Mino Labs, Novartis, Sanofi-Regeneron, and Zylo Therapeutics and is a speaker for AbbVie, Bristol Myers Squibb, Dermavant, Janssen, and Sanofi-Regeneron. SN has received a Pfizer Learning and Change grant and has been an advisor for Pfizer Inc. and is Dermatology editor for the <i>New England Journal of Medicine</i> Healer educational resource.
: Data sharing is not applicable to this article because no datasets were generated or analyzed during the current study.
: Not applicable.
: Not applicable.
: The preparation of this review was supported by Pfizer Inc.
: Not applicable.